Synthesis and Inhibitory Assessment of ACE2 Inhibitors for SARS-CoV-2: An In Silico and In Vitro Study
Year: 2025
Type: article
Abstract: High Resolution Image Download MS PowerPoint Slide The angiotensin-converting enzyme 2 (ACE2) is pivotal as the cellular receptor for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus responsible for COVID-19. This study presents a novel synthetic route for four analogues of MLN-4760, a known inhibitor of ACE2, guided by in silico docking predictions. These synthetic advances enabled in vitro pIC 50 assays confirming the inhibitory potency of the synthesized analogues. Lastly, this route was applied to the synthesis of novel 18 F-labeled ACE2 inhibitors for PET imaging applications.
Source: The Journal of Organic Chemistry
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, University of Oxford, Cardiff University, Medical Research Council, Engineering and Physical Sciences Research Council, School of Chemistry, Cardiff University, NIHR Cambridge Biomedical Research Centre, H2020 European Research Council
Awards: G1680483594, G2493601830, G2537968379, G4655236649, G4753630297, Controlling Membrane Translocation for Artificial Signal Transduction, 18F-Difluoromethylation: The Missing Link in Radiochemistry for Positron Emission Tomography, PET imaging of PARP using 18F-olaparib, Hydrogen Bonding Phase Transfer Catalysis
OpenAlex ID: W4412514023